NAV

COVID19 s-vax loaded autologous dendritic cell vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank Accession Number
DB15814
Background

Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine.

Dendritic Cells (DCs) are showing potential as natural adjuvants for vaccines due to their ability to both prime and boost cell responses; they are considered the most powerful antigen-presenting cells, and are able to present antigens through costimulatory signals required for activation of CD4+ and CD8+ T-cells. DC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19. The rationale is that loading a DC cell with SARS-Cov-2 antigens and administering it as a vaccine can induce a more prolific immune response.

This vaccine was developed and tested by Beijing TIL Therapeutics. As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety and immunogenicity of the vaccine.

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • COVID19 s-vax loaded autologous dendritic cell
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Dillman RO, Cornforth AN, Nistor GI, McClay EF, Amatruda TT, Depriest C: Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. J Immunother Cancer. 2018 Mar 6;6(1):19. doi: 10.1186/s40425-018-0330-1. [Article]
  2. Cohen S, Haimovich J, Hollander N: Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J Immunol. 2009 Feb 1;182(3):1667-73. doi: 10.4049/jimmunol.182.3.1667. [Article]
  3. Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F, Velu T: Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006 Jul;55(7):819-29. doi: 10.1007/s00262-005-0078-6. Epub 2005 Sep 27. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at September 05, 2020 17:53 / Updated at September 06, 2020 08:29